Floatz logo

Ibrutinib

Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1

National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

35 Active assets in the Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 cohort.

Asset / SponsorPhaseRating
Nilotinib
The University of Hong Kong
Phase 2BBB
Cytosin-Arabinosid
Novartis Pharmaceuticals
Phase 3BBB
Blinatumomab
Novartis Pharmaceuticals
Phase 3BBB
METHOTREXATE
Novartis Pharmaceuticals
Phase 3BB
Imatinib
The University of Hong Kong
Phase 3BB

View all 50 →

Same molecule, other indications

Ibrutinib is also rated in:

lymphoid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
70 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →